Janux Therapeutics (NASDAQ: JANX) Surges 40% After Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Hot FDA News Momentum Movers

Janux Therapeutics (JANX) PT Raised to $115 at StifelDecember 3, 2024 8:22 AM William Blair on Janux Therapeutics (JANX): 'Exceeding Investor Expectations and Raising the Bar in mCRPC'December 3, 2024 7:06 AM Janux Therapeutics (JANX) PT Raised to $91 at Leerink PartnersDecember 3, 2024 6:55 AM Stifel Reiterates Buy Rating on Janux Therapeutics (JANX)December 3, 2024 5:27 AM Janux Therapeutics (JANX) PT Raised to $100 at BTIG, 'The World Is Not Enough — 007 Strikes Again Exceeding The Street's Highest Expectations'December 3, 2024 5:26 AM